The field of cancer biology and digestive diseases has increasingly focused on the intricate relationship between microbiota homeostasis and metabolic reprogramming. Metabolic reprogramming is a hallmark of cancer, providing essential intermediates and energy for tumor cell survival and proliferation. Tumor cells exhibit a heterogeneous metabolic phenotype, characterized by diverse metabolic compartments interconnected through the transfer of various catabolites. This metabolic flexibility allows tumor cells to fulfill their heightened biosynthetic and bioenergetic demands while maintaining redox balance. Recent studies have highlighted the role of microbiota imbalance in disrupting the immune microenvironment and contributing to digestive diseases, potentially leading to gastrointestinal cancer development. Microbiota-derived metabolites have been shown to influence cancer progression and treatment responses, including radiotherapy, chemotherapy, and immunotherapy. Despite these advances, the precise mechanisms governing microbiota homeostasis and metabolic reprogramming in cancer and digestive diseases remain largely unexplored, necessitating further investigation.
This research topic aims to provide comprehensive insights into the metabolic plasticity and host-microbiota interactions involved in the initiation and progression of cancers and digestive diseases. Given the heterogeneity of metabolic phenotypes and microbial niches among individuals, the research will focus on utilizing integrated high-throughput technologies, such as single-cell and spatial transcriptomics, 16S ribosomal RNA sequencing, proteomics, and metabolomics. These approaches will help uncover novel biomarkers and mechanisms underlying cancer and digestive disease development. Ultimately, the goal is to establish valuable and personalized therapeutic strategies and evaluate their potential clinical applications.
To gather further insights into the complex interplay between microbiota homeostasis and metabolic reprogramming, we welcome articles addressing, but not limited to, the following themes:
- The dynamic and spatio-temporal landscape of the microbiome in digestive diseases.
- The relationship between microbiota disorders and metabolic alterations in the tumor microenvironment.
- Novel mechanisms of microbiota-derived metabolites in the development of digestive diseases.
- Identification of potential therapeutic strategies targeting metabolism-related signaling through bioactive compounds.
- Catabolites-driven post-translational modifications during cancer progression.
The field of cancer biology and digestive diseases has increasingly focused on the intricate relationship between microbiota homeostasis and metabolic reprogramming. Metabolic reprogramming is a hallmark of cancer, providing essential intermediates and energy for tumor cell survival and proliferation. Tumor cells exhibit a heterogeneous metabolic phenotype, characterized by diverse metabolic compartments interconnected through the transfer of various catabolites. This metabolic flexibility allows tumor cells to fulfill their heightened biosynthetic and bioenergetic demands while maintaining redox balance. Recent studies have highlighted the role of microbiota imbalance in disrupting the immune microenvironment and contributing to digestive diseases, potentially leading to gastrointestinal cancer development. Microbiota-derived metabolites have been shown to influence cancer progression and treatment responses, including radiotherapy, chemotherapy, and immunotherapy. Despite these advances, the precise mechanisms governing microbiota homeostasis and metabolic reprogramming in cancer and digestive diseases remain largely unexplored, necessitating further investigation.
This research topic aims to provide comprehensive insights into the metabolic plasticity and host-microbiota interactions involved in the initiation and progression of cancers and digestive diseases. Given the heterogeneity of metabolic phenotypes and microbial niches among individuals, the research will focus on utilizing integrated high-throughput technologies, such as single-cell and spatial transcriptomics, 16S ribosomal RNA sequencing, proteomics, and metabolomics. These approaches will help uncover novel biomarkers and mechanisms underlying cancer and digestive disease development. Ultimately, the goal is to establish valuable and personalized therapeutic strategies and evaluate their potential clinical applications.
To gather further insights into the complex interplay between microbiota homeostasis and metabolic reprogramming, we welcome articles addressing, but not limited to, the following themes:
- The dynamic and spatio-temporal landscape of the microbiome in digestive diseases.
- The relationship between microbiota disorders and metabolic alterations in the tumor microenvironment.
- Novel mechanisms of microbiota-derived metabolites in the development of digestive diseases.
- Identification of potential therapeutic strategies targeting metabolism-related signaling through bioactive compounds.
- Catabolites-driven post-translational modifications during cancer progression.